graph Evidence gap map comparisons
anti-CTLA-4atezolizumab based treatmentnivolumab based treatmentanti-PD-(L)1Immune checkpoint association
tremelimumab atezolizumab plus cometinib atezolizumab plus SoC nivolumab alone nivolumab followed by ipilimumab nivolumab plus ipilimumab relatlimab plus nivolumab
mML - 1st line (L1)
mML - L1 - all population 7            
mML - L1 - BRAF mutant 2     
mML - L1 - BRAF wild 3       
Comparator:  vs ipilimumab alone;   vs ipilimumab followed by nivolumab;   vs nivolumab alone;   vs Standard of Care (SoC);   vs placebo plus SoC;   vs pembrolizumab alone;   vs dacarbazine; 
Risk of bias:  low;   some concerns;   high;  NA;